Jonathan B Brown
Overview
Explore the profile of Jonathan B Brown including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elgart J, Asteazaran S, De La Fuente J, Camillucci C, Brown J, Gagliardino J
Int J Public Health
. 2014 Sep;
59(5):851-7.
PMID: 25189732
Objectives: To estimate direct and indirect costs of care of type 2 diabetes (T2DM) and its complications in Argentina, and compare them with those recorded in people without diabetes (ND)....
2.
Association between socioeconomic status, type 2 diabetes and its chronic complications in Argentina
Elgart J, Caporale J, Asteazaran S, De La Fuente J, Camilluci C, Brown J, et al.
Diabetes Res Clin Pract
. 2014 Mar;
104(2):241-7.
PMID: 24629409
Aim: To compare the socioeconomic status (SES) of people with type 2 diabetes (T2DM) in Argentina (Córdoba) with and without major chronic complications of diabetes, with that recorded in persons...
3.
Nichols G, Conner C, Brown J
Curr Med Res Opin
. 2010 Jul;
26(9):2127-35.
PMID: 20658898
Objective: To document the extent to which drug naïve patients with diabetes continued newly initiated metformin monotherapy, and who subsequently experienced primary failure or therapeutic success. Research Design And Methods:...
4.
Blum S, Vardi M, Brown J, Russell A, Milman U, Shapira C, et al.
Pharmacogenomics
. 2010 Apr;
11(5):675-84.
PMID: 20415560
Aims: Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is...
5.
Brown J, Conner C, Nichols G
Diabetes Care
. 2009 Dec;
33(3):501-6.
PMID: 20040656
OBJECTIVE We sought to document the secondary failure rate of metformin monotherapy in a clinical practice setting and to explore factors that predict therapeutic failure. RESEARCH DESIGN AND METHODS We...
6.
Nichols G, Ambegaonkar B, Sazonov V, Brown J
Am J Cardiol
. 2009 Dec;
104(12):1689-94.
PMID: 19962476
Statin treatment targeting low-density lipoprotein (LDL) cholesterol is widely used for cardiovascular risk reduction, but many statin users still face greatly elevated risks. Some experts advocate additional therapy that targets...
7.
Nichols G, Gandra S, Chiou C, Anthony M, Alexander-Bridges M, Brown J
Curr Med Res Opin
. 2009 Nov;
26(1):9-15.
PMID: 19891525
Objective: Although insulin is the most effective diabetes medication for lowering blood glucose, how insulin is used in clinical practice and how well patients respond to insulin therapy over the...
8.
Nichols G, Brown J
Am J Manag Care
. 2008 Sep;
14(9):574-80.
PMID: 18778172
Background: Investigators from the Framingham Offspring Study (FOS) recently proposed a new simple point score for estimating 8-year diabetes mellitus (DM) risk. Objectives: To validate prediction models and to compare...
9.
Nichols G, Hillier T, Brown J
Am J Med
. 2008 May;
121(6):519-24.
PMID: 18501234
Purpose: The study compares the risk of incident diabetes associated with fasting plasma glucose levels in the normal range, controlling for other risk factors. Methods: We identified 46,578 members of...
10.
Nichols G, Alexander C, Girman C, Kamal-Bahl S, Brown J
Endocr Pract
. 2007 Mar;
13(1):37-44.
PMID: 17360299
Objective: To revise older estimates of secondary failure that may no longer describe the contemporary pattern of sulfonylurea (SU) monotherapy and to identify predictors of such failure. Methods: We identified...